Bispecific antibody treatment of murine B cell lymphoma

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 162-165

  De Jonge, Jan ^a   Heirman, Carlo ^a   De Veerman, Marijke ^a   Van Meirvenne, Sonja ^a   Demanet, Christian ^a   Brissinck, Jana ^a   Thielemens, Kris ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

B cell lymphoma immunotherapy; Bispecific antibodies; Fusion protein

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; CYTOTOXICITY; HYBRIDOMA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, SURFACE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN M; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; TUMOR CELLS, CULTURED;

EID: 0030772182     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050423     Document Type: Article

References (11)

1. Brissinck J, Demanet C, Moser M, Leo O, Thielemans K (1991) Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 147:4019
2. Brissinck J, Demanet C, Thielemans K (1995) Bispecific antibody in T-cell targeting. Tumor Targeting 1:195
3. De Gast GC, Van-Houten AA, Haagen IA, Klein S, De Weger RA, Van-Dijk A, Phillips J, Clark M, Bast BJ 81995) Clinical experience with DC3 x CD19 bispecific antibodies in patients with B-cell malignancies. J Hematother 4:433
4. De Jonge J, Brissinck J, Heirman C, Demanet C, Leo O, Moser M, Thielemans K (1995) Production and characterization of bispecific single-chain antibody fragments. Mol Immunol 32:1405
5. Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K (1991) Treatment of murine B-cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol 147:1091
6. Demanet C, Brissinck J, Leo O, Moser M, Thielemans K (1994) Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma. Cancer Res 54:2973
7. Demanet C, Brissinck J, De Jonge J, Thielemans K (1995) In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in BCL1 lymphoma. J Hematotherapy 4:363
8. Demanet C, Brissinck J, De Jonge J, Thielemans K (1996) Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced co-stimulation. Blood 87:4390
9. Holliger P, Brissinck J, Wiliams R, Thielemans K, Winter G (1996) Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 9:299
10. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trumper L, Harmann F, Diehl V, Lier R van, Pfreudschuh M (1994) Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833
11. Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY (1994) The role of T-cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol 152:2385